250 related articles for article (PubMed ID: 28894890)
1. New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma.
Ersoy TF; Keil VC; Hadizadeh DR; Gielen GH; Fimmers R; Waha A; Heidenreich B; Kumar R; Schild HH; Simon M
Neuroradiology; 2017 Dec; 59(12):1223-1231. PubMed ID: 28894890
[TBL] [Abstract][Full Text] [Related]
2. Prognostic quality of activating TERT promoter mutations in glioblastoma: interaction with the rs2853669 polymorphism and patient age at diagnosis.
Spiegl-Kreinecker S; Lötsch D; Ghanim B; Pirker C; Mohr T; Laaber M; Weis S; Olschowski A; Webersinke G; Pichler J; Berger W
Neuro Oncol; 2015 Sep; 17(9):1231-40. PubMed ID: 25681309
[TBL] [Abstract][Full Text] [Related]
3. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas.
Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M
J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520
[TBL] [Abstract][Full Text] [Related]
4. MRI Features Associated with TERT Promoter Mutation Status in Glioblastoma.
Ivanidze J; Lum M; Pisapia D; Magge R; Ramakrishna R; Kovanlikaya I; Fine HA; Chiang GC
J Neuroimaging; 2019 May; 29(3):357-363. PubMed ID: 30644143
[TBL] [Abstract][Full Text] [Related]
5. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.
Simon M; Hosen I; Gousias K; Rachakonda S; Heidenreich B; Gessi M; Schramm J; Hemminki K; Waha A; Kumar R
Neuro Oncol; 2015 Jan; 17(1):45-52. PubMed ID: 25140036
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of TERT promoter mutations in glioblastomas is modified by the rs2853669 single nucleotide polymorphism.
Batista R; Cruvinel-Carloni A; Vinagre J; Peixoto J; Catarino TA; Campanella NC; Menezes W; Becker AP; de Almeida GC; Matsushita MM; Clara C; Neder L; Viana-Pereira M; Honavar M; Castro L; Lopes JM; Carvalho B; Vaz RM; Máximo V; Soares P; Sobrinho-Simões M; Reis RM; Lima J
Int J Cancer; 2016 Jul; 139(2):414-23. PubMed ID: 26914704
[TBL] [Abstract][Full Text] [Related]
7. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
[TBL] [Abstract][Full Text] [Related]
8. Brain regions associated with telomerase reverse transcriptase promoter mutations in primary glioblastomas.
Fan X; Wang Y; Liu Y; Liu X; Zhang C; Wang L; Li S; Ma J; Jiang T
J Neurooncol; 2016 Jul; 128(3):455-62. PubMed ID: 27230769
[TBL] [Abstract][Full Text] [Related]
9. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes.
Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M
Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284
[TBL] [Abstract][Full Text] [Related]
10. TERT promoter mutations and polymorphisms as prognostic factors in primary glioblastoma.
Mosrati MA; Malmström A; Lysiak M; Krysztofiak A; Hallbeck M; Milos P; Hallbeck AL; Bratthäll C; Strandéus M; Stenmark-Askmalm M; Söderkvist P
Oncotarget; 2015 Jun; 6(18):16663-73. PubMed ID: 26143636
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations in primary and secondary glioblastomas.
Nonoguchi N; Ohta T; Oh JE; Kim YH; Kleihues P; Ohgaki H
Acta Neuropathol; 2013 Dec; 126(6):931-7. PubMed ID: 23955565
[TBL] [Abstract][Full Text] [Related]
12. Deep Learning Radiomics for the Assessment of Telomerase Reverse Transcriptase Promoter Mutation Status in Patients With Glioblastoma Using Multiparametric MRI.
Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Lei Y; Huang B
J Magn Reson Imaging; 2023 Nov; 58(5):1441-1451. PubMed ID: 36896953
[TBL] [Abstract][Full Text] [Related]
13. Multiparametric MRI-based fusion radiomics for predicting telomerase reverse transcriptase (TERT) promoter mutations and progression-free survival in glioblastoma: a multicentre study.
Zhang H; Zhang H; Zhang Y; Zhou B; Wu L; Yang W; Lei Y; Huang B
Neuroradiology; 2024 Jan; 66(1):81-92. PubMed ID: 37978079
[TBL] [Abstract][Full Text] [Related]
14. A radiomics-based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma.
Li Y; Chen L; Huang L; Li X; Huang Q; Tang L; Huang Z; Zhu L; Li T
Brain Behav; 2024 May; 14(5):e3528. PubMed ID: 38798094
[TBL] [Abstract][Full Text] [Related]
15. Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.
Ahn SS; Shin NY; Chang JH; Kim SH; Kim EH; Kim DW; Lee SK
J Neurosurg; 2014 Aug; 121(2):367-73. PubMed ID: 24949678
[TBL] [Abstract][Full Text] [Related]
16. Discriminating association of a common telomerase reverse transcriptase promoter polymorphism with telomere parameters in non-small cell lung cancer with or without epidermal growth factor receptor mutation.
Yuan P; Huang S; Bao FC; Cao JL; Sheng HX; Shi L; Lv W; Hu J
Eur J Cancer; 2019 Oct; 120():10-19. PubMed ID: 31446212
[TBL] [Abstract][Full Text] [Related]
17. Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss.
Arita H; Narita Y; Fukushima S; Tateishi K; Matsushita Y; Yoshida A; Miyakita Y; Ohno M; Collins VP; Kawahara N; Shibui S; Ichimura K
Acta Neuropathol; 2013 Aug; 126(2):267-76. PubMed ID: 23764841
[TBL] [Abstract][Full Text] [Related]
18. Concurrent TERT promoter and BRAF V600E mutation in epithelioid glioblastoma and concomitant low-grade astrocytoma.
Matsumura N; Nakajima N; Yamazaki T; Nagano T; Kagoshima K; Nobusawa S; Ikota H; Yokoo H
Neuropathology; 2017 Feb; 37(1):58-63. PubMed ID: 27302309
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
[TBL] [Abstract][Full Text] [Related]
20. MRI Features May Predict Molecular Features of Glioblastoma in
Park CJ; Han K; Kim H; Ahn SS; Choi D; Park YW; Chang JH; Kim SH; Cha S; Lee SK
AJNR Am J Neuroradiol; 2021 Mar; 42(3):448-456. PubMed ID: 33509914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]